Clinical efficacy and tolerability of Xeomin® in the treatment of blepharospasm

European Journal of Neurology

Volumn 16, Issue SUPPL. 2, 2009, Pages 14-18

  Jankovic, J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Blepharospasm; Botulinum toxin type A; Efficacy; Safety; Xeomin

Indexed keywords

BOTULINUM TOXIN A;

ABNORMAL VISION; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BIOEQUIVALENCE; BLEPHAROSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULARY; DRUG POTENCY; DRUG SAFETY; DYSPNEA; FACE EDEMA; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; JANKOVIC RATING SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROMUSCULAR BLOCKING; PARESTHESIA; PHOTOPHOBIA; PRIORITY JOURNAL; PTOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; XEROPHTHALMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-DYSKINESIA AGENTS; BLEPHAROPTOSIS; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 72849127554     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02880.x     Document Type: Article

References (22)

1. Aramideh M, Bour LJ, Koelman JH, et al. Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition. Clinical and pathological considerations. Brain 1994 117 : 1457 1474.
2. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005 64 : 1949 1951.
3. Comella CL, Jankovic J, Shannon KM, et al. Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005 65 : 1423 1429.
4. Dressler D, Comella CL. Comparative clinical trials of botulinum toxins. In : Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N, eds. Botulinum Toxin. Therapeutic Clinical Practice and Science. Philadelphia, PA : Saunders (Elsevier), 2009 : 398 405.
5. Girlanda P, Quartarone A, Sinicropi S, et al. Unilateral injection of botulinum toxin in blepharospasm: single fiber electomicrography and blink reflex study. Mov Disord 1996 11 : 27 31.
6. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 1988 51 : 767 772.
7. Hallett M, Evinger C, Jankovic J, Stacy M, BEBRF International Workshop. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008 71 : 1275 1282.
8. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 1984 16 : 371 376.
9. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987 37 : 616 623.
10. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003 60 : 1186 1188.
11. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 2009a 24 : 407 413.
12. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of NT 201 (Botulinum neurotoxin free from complexing proteins) in blepharospasm. Neurology 2009b 72 (Suppl. 3 A346.
13. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin®) in focal dystonia. Drugs 2007 67 : 669 683. (Pubitemid 46535642)
14. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008 115 : 585 591.
15. Kenney C, Jankovic J. Botulinum neurotoxin treatment of cranial-cervical dystonia. In : Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N, eds. Botulinum Toxin. Therapeutic Clinical Practice and Science. Philadelphia, PA : Saunders (Elsevier), 2009 : 92 101.
16. Lindeboom R, De Haan R, Aramideh M, Speelman JD. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord 1995 10 : 444 449.
17. Pappert EJ, Germanson T, The Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008 23 : 510 517.
18. Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006 113 : 303 312.
19. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 70 : 1699 1706.
20. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005 65 : 765 767. (Pubitemid 41285865)
21. Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport®) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008 14 : 407 414.
22. Van Ermengem E. Uber einen neuen anaëroben bacillus une seine beziehungen zum botulismus. Z Hyg Infektionskr 1897 26 : 1 56 (republished as: A new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1979; 1: 701-719.